Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 1,129 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 1,129 shares of the company's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total transaction of $61,914.36. Following the completion of the transaction, the insider now owns 166,234 shares in the company, valued at approximately $9,116,272.56. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total value of $127,332.00.
• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.49, for a total value of $668,625.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total transaction of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.43, for a total value of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total value of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.88, for a total transaction of $224,250.00.

Akero Therapeutics Stock Performance

NASDAQ AKRO traded down $0.17 on Monday, reaching $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. The stock has a market cap of $4.31 billion, a P/E ratio of -27.71 and a beta of -0.16. Akero Therapeutics, Inc. has a 12-month low of $21.02 and a 12-month high of $58.40. The business's 50-day moving average price is $45.88 and its 200 day moving average price is $41.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. As a group, equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Trading of Akero Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AKRO. Rhumbline Advisers lifted its position in Akero Therapeutics by 1.3% in the fourth quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock valued at $2,940,000 after purchasing an additional 1,310 shares during the period. Handelsbanken Fonder AB raised its stake in shares of Akero Therapeutics by 5.0% during the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock worth $584,000 after buying an additional 1,000 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Akero Therapeutics in the 4th quarter valued at approximately $320,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Akero Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock valued at $15,042,000 after buying an additional 8,096 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after buying an additional 8,147 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Citigroup decreased their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. HC Wainwright raised their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Finally, Bank of America increased their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a report on Tuesday, May 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $82.50.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.